Immunostimulatory CpG SD-101 + RT in Recurrent/Progressive Lymphoma After Allogeneic Hematopoietic Cell Transplantation (HCT)
| Status: | Terminated |
|---|---|
| Conditions: | Lymphoma |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 11/19/2016 |
| Start Date: | August 2012 |
| End Date: | November 2014 |
Intratumoral Injection of an Immunostimulatory CpG, SD-101, Combined With Local Radiation for the Treatment of Recurrent or Progressive Lymphoma After Allogeneic Hematopoietic Cell Transplantation
For patients with lymphoma that recurs after chemotherapy, bone marrow transplantation using
cells from a healthy donor represents potentially curative treatment. In these individuals,
cure is possible because transplantation of healthy donor immune cells can fight the
lymphoma in the patient. The goal of this work is to test a strategy that activates the
healthy donor immune cells so that they more effectively fight lymphoma and can result in an
increased cure rate for these patients. Our group has previously studied CpG, an immune
activating medication, in patients with lymphoma and demonstrated modest anti-tumor
responses. We now have a more potent form of CpG which we intend to test to see if it will
better activate the donor immune cells and result in shrinkage of tumor throughout the
entire body, not just at the injected site.
cells from a healthy donor represents potentially curative treatment. In these individuals,
cure is possible because transplantation of healthy donor immune cells can fight the
lymphoma in the patient. The goal of this work is to test a strategy that activates the
healthy donor immune cells so that they more effectively fight lymphoma and can result in an
increased cure rate for these patients. Our group has previously studied CpG, an immune
activating medication, in patients with lymphoma and demonstrated modest anti-tumor
responses. We now have a more potent form of CpG which we intend to test to see if it will
better activate the donor immune cells and result in shrinkage of tumor throughout the
entire body, not just at the injected site.
Patients will receive low dose radiation to all bulky or symptomatic lymph nodes on days -2
and -1. SD-101 will be administered intratumorally to the single largest palpable node
within 24 hours after completion of radiation, on day 0. Two additional intratumoral SD-101
injections will be performed on days 7 (+/- 2 days) and 14 (+/- 2 days). This is a dose
ranging study using a 3+3 design with a definition of maximum tolerated dose (MTD) which our
group has found acceptable in the past. The first cohort of patients will receive a SD-101
dose of 0.3 mg per injection. The dose will be escalated to 1 mg and 3 mg based on dose
limiting toxicity (DLT).
and -1. SD-101 will be administered intratumorally to the single largest palpable node
within 24 hours after completion of radiation, on day 0. Two additional intratumoral SD-101
injections will be performed on days 7 (+/- 2 days) and 14 (+/- 2 days). This is a dose
ranging study using a 3+3 design with a definition of maximum tolerated dose (MTD) which our
group has found acceptable in the past. The first cohort of patients will receive a SD-101
dose of 0.3 mg per injection. The dose will be escalated to 1 mg and 3 mg based on dose
limiting toxicity (DLT).
Inclusion Criteria:
- Biopsy-confirmed relapsed, refractory, or progressive NHL or HL (Refer to Section
3.2.1 for excluded subtypes)
- At least 3 sites of disease
1. One for diagnosis (lymph node or bone marrow biopsy)
2. One palpable for treatment
3. One measurable radiographically
- > 60 days after RIC allogeneic transplant for lymphoma
- 18 years of age or older
- Mixed (5-95%) or complete (>95%) chimerism
- Eastern Oncology Cooperative Group (ECOG) performance status ≤ 2
- ANC >1000/mm3, platelets >50,000/mm3
- Total bilirubin ≤ 2.5 mg/dL, AST and ALT < 3 times upper limit of normal
- Serum creatinine ≤ 3 mg/dL
- No chemotherapy, RT, DLI or biologic therapy for lymphoma at least 4 weeks prior to
scheduled treatment
- Minimal immunosuppression (defined as monotherapy with ≤ 10 mg prednisone daily, ≤
200 mg cyclosporine daily, or ≤ 2 mg tacrolimus daily) at least 2 weeks prior to
scheduled treatment
Exclusion Criteria:
- HIV associated lymphoma
- Acute GVHD at time of enrollment (history of treated and resolved GVHD is permitted)
- Active infection within 14 days prior to scheduled treatment
- Active Cytomegalovirus (CMV) disease at the time of enrollment
- Pre-existing autoimmune or antibody mediated disease (including systemic lupus
erythematosus, rheumatoid arthritis, multiple sclerosis, Sjogren's syndrome, and
autoimmune thrombocytopenia)
- Pregnant
We found this trial at
1
site
Click here to add this to my saved trials
